12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ocriplasmin regulatory update

EMA's CHMP issued a positive opinion recommending approval of ThromboGenics' Jetrea ocriplasmin to treat vitreomacular traction, including when associated with a macular hole of <=400 um in...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >